Verrica Q1 Revenue Jumps 46% on Strong YCANTH Demand
VRCA has more than doubled off its 52-week low of $3.28 on light trading volume (0.3× avg).
Summary
Verrica Pharmaceuticals reported a significant 46% year-over-year increase in Q1 revenue, driven by record demand for its YCANTH product and its commercial launch in Japan. This strong top-line performance is a critical positive for the company, especially in light of the 'going concern' warning noted in its last 10-K. However, the adjusted EPS loss widened to $0.41 per share, missing the analyst consensus of $0.38. The company also announced progress in its Phase 3 common warts trial enrollment and plans to initiate a second Phase 3 trial for YCANTH in mid-2026, alongside preparations for a VP-315 basal cell carcinoma study. Traders will be watching for sustained YCANTH sales momentum and further clinical trial advancements as key catalysts.
At the time of this announcement, VRCA was trading at $7.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $122.8M. The 52-week trading range was $3.28 to $9.82. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.